Giotrif in non‑small cell lung cancer therapy – case report
MUDr. Libor Havel
Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
The activating epidermal growth factor receptor mutation is present in almost 50% of patients with advanced non-small cell lung cancer, who are of Asian ethnicity1 compared with only 12% in the Caucasian population.2 These molecular alterations predict sensitivity to first and second generation epidermal growth factor receptor tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib. Response rate and progression-free survival with epidermal growth factor receptor tyrosine kinase inhibitors are superior to standard first-line platinum doublet chemotherapy, making them the standard of care.
non-small cell lung cancer, epidermal growth factor receptor mutations, afatinib, gefitinib, erlotinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...